Cognition Therapeutics, Inc. Increase (Decrease) in Other Current Liabilities
Cognition Therapeutics, Inc. (CGTX) reported Increase (Decrease) in Other Current Liabilities of $1.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2022-05-11
- Cognition Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2022-03-31 was $1.00K.
- Cognition Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2021-12-31 was -$160.00K.
- Cognition Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2021-03-31 was -$253.00K.
- Cognition Therapeutics, Inc. increase (decrease) in other current liabilities for the quarter ending 2020-12-31 was -$495.00K.
- Cognition Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2021 was $501.00K, a 98.81% increase from fiscal 2020.
- Cognition Therapeutics, Inc. increase (decrease) in other current liabilities for fiscal 2020 was $252.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-11 | -$159.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | -$160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $501.00K 10-K · filed 2022-03-30 | ||
| 2021-09-30 | $661.00K 10-Q · filed 2021-11-17 | |||
| 2021-03-31 | -$253.00K 10-Q · filed 2022-05-11 | -$748.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $252.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $747.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |